论文部分内容阅读
目的:观察分析莫沙必利联合舒肝解郁胶囊与单药应用治疗功能性消化不良(FD)的临床效果。方法:选取本院2013年6月-2014年6月收治的90例FD患者,运用随机数字表法分为观察组(45例)及对照组(45例),对照组患者采用莫沙必利治疗,观察组患者采用莫沙必利联合舒肝解郁胶囊治疗,科学评估两组患者临床治疗效果。结果:观察组患者临床治疗总有效率95.56%,高于对照组71.11%,治疗后观察组患者症状积分均低于对照组,随访复发率6.67%,低于对照组28.89%,差异具有统计学意义(P<0.05),不良反应比较,差异无统计学意义(P>0.05)。结论:在FD治疗过程中,莫沙必利与舒肝解郁胶囊联合治疗,可明显缓解临床症状,减少复发风险,不良反应少,疗效安全显著。
Objective: To observe and analyze the clinical effect of mosapride combined with Shugan Jieyu capsule and single drug in the treatment of functional dyspepsia (FD). Methods: Ninety FD patients admitted to our hospital from June 2013 to June 2014 were randomly divided into observation group (45 cases) and control group (45 cases) using random number table. Patients in the control group were treated with mosapride Treatment, observation group patients treated with Mosapride combined Shugan Jieyu capsule, the clinical evaluation of two groups of patients scientifically. Results: The total effective rate of clinical treatment in observation group was 95.56%, higher than 71.11% in control group. After treatment, symptom scores in observation group were lower than those in control group. The follow-up recurrence rate was 6.67%, which was lower than 28.89% in control group. The difference was statistically significant Significance (P <0.05), adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion: During the treatment of FD, mosapride and Shugan Jieyu capsules combined treatment can significantly relieve clinical symptoms, reduce the risk of relapse, fewer adverse reactions, the effect of safety significantly.